IP Group Invests £4m in Microbiotica Financing Round
Microbiotica said the cash will support advancing its potential ulcerative colitis treatment into a phase two trial. Its initial study showed “statistically significant improvements,” according to the supplied report.
Clinical-stage biopharma company Microbiotica said the funding will support moving its potential ulcerative colitis treatment into a phase two trial. The company is developing orally dosed, precision microbiome medicines. An initial study showed “statistically significant improvements…”